Drug profile · INN
duloxetine hydrochloride
CYMBALTA PARTIAL CHANGE APPROVAL
duloxetine hydrochloride (CYMBALTA PARTIAL CHANGE APPROVAL) is a norepinephrine transporter inhibitor. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: oral. Current US regulatory status: approved.
Drug details — duloxetine hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 20
- Programs
- 3
- Data quality
- 0.89
Quick answer
duloxetine hydrochloride (CYMBALTA PARTIAL CHANGE APPROVAL) is a norepinephrine transporter inhibitor. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Norepinephrine transporter inhibitor
Primary target: Sodium-dependent noradrenaline transporter
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
-
US 12428389
Diarylamide compound and application thereof
granted -
US 12258317
Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof
granted -
US 12194065
Methods and compositions to enhance metabolic detoxification systems
granted -
US 12171761
Vilazodone inclusion complexes, compositions and preparation thereof
granted -
US 12128044
Fused tricyclic compounds and uses thereof in medicine
granted -
US 11679143
FGF21 variant, fusion protein and application thereof
granted -
US 11517569
Vilazodone inclusion complexes, compositions and preparation thereof
granted -
US 11447498
Fused tetracyclic compounds and uses thereof in medicine
granted -
US 11396495
Amine compound for inhibiting SSAO/VAP-1 and use thereof
granted -
US 11285153
Substituted pyrimidine piperazine compound and use thereof
granted -
US 11261190
Dihydropyrimidine compounds and uses thereof in medicine
granted -
US 11242335
Fluorine-substituted indazole compounds and uses thereof
granted -
US 11142527
Dihydropyrimidine compounds and uses thereof in medicine
granted -
US 11122832
Methods and compositions to improve weight loss and cardiometabolic health beyond diet and excercise
granted -
US 10966970
Fused tricyclic compounds and uses thereof in medicine
granted -
US 10927089
Diaryl thioether piperazine compounds, preparation methods and uses thereof
granted -
US 10751339
Substituted aminopyrimidine compounds and methods of use
granted -
US 10688090
Vilazodone inclusion complexes, compositions and preparation thereof
granted -
US 10316025
Substituted piperazine compounds and methods of use and use thereof
granted -
US 10266521
Substituted heteroaryl compounds and methods of use
granted
Frequently asked questions
What is duloxetine hydrochloride?
duloxetine hydrochloride (CYMBALTA PARTIAL CHANGE APPROVAL) is a norepinephrine transporter inhibitor. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for duloxetine hydrochloride?
CYMBALTA PARTIAL CHANGE APPROVAL is a marketed brand name for duloxetine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of duloxetine hydrochloride?
duloxetine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.